title: How smart is peptide receptor radionuclide therapy of neuroendocrine tumors especially in the salvage setting? The clinician's perspective.
authors.affiliation: Department of Nuclear Medicine, Campus Virchow-Klinikum, Charité University Hospital, Berlin, Germany, vikas.prasad@charite.de.
authors.forename: Vikas
authors.initials: V
authors.lastname: Prasad
authors.forename: Winfried
authors.initials: W
authors.lastname: Brenner
authors.forename: Irvin M
authors.initials: IM
authors.lastname: Modlin
mesh_terms: D004067:Digestive System Neoplasms / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D016879:Salvage Therapy
chemical_list: C554548:177Lu-octreotate; D019275:Radiopharmaceuticals; D015282:Octreotide